<?xml version="1.0" encoding="UTF-8"?>
<Pathway xmlns="http://pathvisio.org/GPML/2013a" Name="Fluoropyrimidine activity" Organism="Homo sapiens" License="CC BY 2.0">
  <Comment Source="WikiPathways-description">The main mechanism of 5-FU activation is conversion to fluorodeoxyuridine monophosphate (FdUMP) which inhibits the enzyme thymidylate synthase (TYMS), an important part of the folate-homocysteine cycle and purine and pyrimidine synthesis The conversion of 5-FU to FdUMP can occur via thymidylate phosphorylase (TYMP) to fluorodeoxyuridine (FUDR) and then by the action of thymidine kinase to FdUMP or indirectly via fluorouridine monophosphate (FUMP) or fluroridine (FUR) to fluorouridine diphosphate (FUDP) and then ribonucleotide reductase action to FdUDP and FdUMP. FUDP and FdUDP can also be converted to FUTP and FdUTP and incorporated into RNA and DNA respectively which also contributes to the pharmacodynamic actions of fluoropyrimidines.

Sources: [https://www.pharmgkb.org/pathway/PA150653776 PharmGKB:Fluoropyrimidine Pharmacokinetics], [https://www.pharmgkb.org/pathway/PA165291507 PharmGKB:Fluoropyrimidine Pharmacodynamics], [http://en.wikipedia.org/wiki/Fluorouracil Wikipedia:Fluorouracil]

Proteins on this pathway have targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP1601 CPTAC Assay Portal]</Comment>
  <Comment Source="WikiPathways-category">Metabolic Process</Comment>
  <Comment Source="WikiPathways-category">Cellular Process</Comment>
  <BiopaxRef>a3c</BiopaxRef>
  <BiopaxRef>f20</BiopaxRef>
  <BiopaxRef>a45</BiopaxRef>
  <BiopaxRef>a42</BiopaxRef>
  <BiopaxRef>bf9</BiopaxRef>
  <BiopaxRef>b9d</BiopaxRef>
  <BiopaxRef>b66</BiopaxRef>
  <BiopaxRef>b8e</BiopaxRef>
  <BiopaxRef>dd6</BiopaxRef>
  <BiopaxRef>d42</BiopaxRef>
  <BiopaxRef>fa0</BiopaxRef>
  <BiopaxRef>d3c</BiopaxRef>
  <Graphics BoardWidth="699.0" BoardHeight="1022.0"/>
  <DataNode TextLabel="5-fluorouracil (5-FU)" GraphId="a4b39" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="Capecitabine" GraphId="a64c7" Type="Metabolite">
    <BiopaxRef>c1f</BiopaxRef>
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="FUR" GraphId="a6a61" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="5-dFUR" GraphId="a7f59" Type="Metabolite">
    <BiopaxRef>ffd</BiopaxRef>
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="dTMP" GraphId="a85a1" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="FUTP" GraphId="ab957" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="FUPA" GraphId="ae234" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="FdUTP" GraphId="af674" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="UPP1" GraphId="b1f9d" Type="GeneProduct" GroupRef="a284d">
        </DataNode>
  <DataNode TextLabel="TK1" GraphId="b2eb1" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="5-hydroxytegafur" GraphId="b4e64" Type="Metabolite">
    <BiopaxRef>e0c</BiopaxRef>
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="SLC22A7" GraphId="b82b7" Type="GeneProduct">
    <BiopaxRef>bb0</BiopaxRef>
        </DataNode>
  <DataNode TextLabel="ABCC5" GraphId="b9ed3" Type="GeneProduct" GroupRef="f3ea1">
        </DataNode>
  <DataNode TextLabel="DHFR" GraphId="bd171" Type="GeneProduct">
    <BiopaxRef>d3c</BiopaxRef>
        </DataNode>
  <DataNode TextLabel="CDA" GraphId="bec21" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="TDG" GraphId="c0e49" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="Tegafur" GraphId="c3c32" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="Leucovorin" GraphId="c458b" Type="Metabolite">
    <BiopaxRef>e79</BiopaxRef>
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="ABCC3" GraphId="c47c4" Type="GeneProduct" GroupRef="f3ea1">
        </DataNode>
  <DataNode TextLabel="UPP2" GraphId="c67ea" Type="GeneProduct" GroupRef="c474a">
        </DataNode>
  <DataNode TextLabel="DPYD" GraphId="c876f" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="MIR29C" GraphId="c8a9b" Type="GeneProduct">
    <Graphics Color="990099"/>
    </DataNode>
  <DataNode TextLabel="UPP1" GraphId="cee94" Type="GeneProduct" GroupRef="c474a">
        </DataNode>
  <DataNode TextLabel="FPGS" GraphId="cfb65" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="ABCC4" GraphId="d0471" Type="GeneProduct" GroupRef="f3ea1">
        </DataNode>
  <DataNode TextLabel="SMUG1" GraphId="d083c" Type="GeneProduct">
    <BiopaxRef>cae</BiopaxRef>
        </DataNode>
  <DataNode TextLabel="TYMS" GraphId="d0969" Type="GeneProduct">
    <BiopaxRef>ff5</BiopaxRef>
    <BiopaxRef>b0a</BiopaxRef>
    <BiopaxRef>f61</BiopaxRef>
    <BiopaxRef>c39</BiopaxRef>
    <BiopaxRef>e25</BiopaxRef>
        </DataNode>
  <DataNode TextLabel="TYMP" GraphId="d1fb1" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="MTHFR" GraphId="d2966" Type="GeneProduct">
    <BiopaxRef>d42</BiopaxRef>
        </DataNode>
  <DataNode TextLabel="dUMP" GraphId="d2ec5" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="DPYS" GraphId="d356e" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="RRM1" GraphId="d55e6" Type="GeneProduct" GroupRef="f2003">
        </DataNode>
  <DataNode TextLabel="UMPS" GraphId="d5a84" Type="GeneProduct" GroupRef="d7a41">
        </DataNode>
  <DataNode TextLabel="DNA Repair" GraphId="d8b62" Type="Pathway">
    <BiopaxRef>f96</BiopaxRef>
    <BiopaxRef>aa3</BiopaxRef>
    <BiopaxRef>dae</BiopaxRef>
    <Graphics Color="009900"/>
    </DataNode>
  <DataNode TextLabel="5-FU" GraphId="d93a5" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="FUDP" GraphId="d9509" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="UCK1" GraphId="d9856" Type="GeneProduct" GroupRef="a0a40">
        </DataNode>
  <DataNode TextLabel="XRCC3" GraphId="d9c06" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="FUMP" GraphId="da52d" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="ERCC2" GraphId="da8b6" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="Folate Cycle" GraphId="db298" Type="Pathway">
    <BiopaxRef>ad5</BiopaxRef>
    <Graphics Color="009900"/>
    </DataNode>
  <DataNode TextLabel="CES1" GraphId="ddbcb" Type="GeneProduct" GroupRef="d0388">
        </DataNode>
  <DataNode TextLabel="UCK2" GraphId="de738" Type="GeneProduct" GroupRef="a0a40">
        </DataNode>
  <DataNode TextLabel="5-FU" GraphId="df15b" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="FBAL" GraphId="df25b" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="FUTP" GraphId="df27a" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="5,10-Methylenetetrahydrofolate" GraphId="dfc35" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="FdUTP" GraphId="e112d" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="GGH" GraphId="e259d" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="CYP2A6" GraphId="e59ab" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="FdUDP" GraphId="e5c13" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="ABCG2" GraphId="e6724" Type="GeneProduct" GroupRef="a95fd">
    <BiopaxRef>f4c</BiopaxRef>
    <BiopaxRef>d5d</BiopaxRef>
        </DataNode>
  <DataNode TextLabel="5-FU" GraphId="e7910" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="Dihydrofolate" GraphId="e7e11" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="TP53" GraphId="e8317" Type="GeneProduct">
    <BiopaxRef>a64</BiopaxRef>
        </DataNode>
  <DataNode TextLabel="RRM2" GraphId="ec794" Type="GeneProduct" GroupRef="f2003">
        </DataNode>
  <DataNode TextLabel="Apoptosis" GraphId="ecb2f" Type="Pathway">
    <Graphics Color="009900"/>
    </DataNode>
  <DataNode TextLabel="FUDR" GraphId="edd9a" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="FdUMP" GraphId="ef347" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="FdUMP" GraphId="f066c" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="5-dFCR" GraphId="f1549" Type="Metabolite">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="SLC29A1" GraphId="f3966" Type="GeneProduct">
    <BiopaxRef>cf4</BiopaxRef>
    <BiopaxRef>e3f</BiopaxRef>
        </DataNode>
  <DataNode TextLabel="UPB1" GraphId="f3ee2" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="UPP2" GraphId="f6b42" Type="GeneProduct" GroupRef="a284d">
        </DataNode>
  <DataNode TextLabel="TYMP" GraphId="f8204" Type="GeneProduct" GroupRef="c474a">
        </DataNode>
  <DataNode TextLabel="PPAT" GraphId="fa047" Type="GeneProduct" GroupRef="d7a41">
        </DataNode>
  <DataNode TextLabel="ABCC4" GraphId="fbecf" Type="GeneProduct" GroupRef="a95fd">
        </DataNode>
  <DataNode TextLabel="DHFU" GraphId="fde63" Type="Metabolite">
    <BiopaxRef>ba0</BiopaxRef>
    <BiopaxRef>dfc</BiopaxRef>
    <BiopaxRef>cb2</BiopaxRef>
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="CES2" GraphId="fffc8" Type="GeneProduct" GroupRef="d0388">
        </DataNode>
  <Interaction GraphId="a234c">
    <Graphics>
      <Point GraphRef="d9509"/>
      <Point GraphRef="e5c13" ArrowHead="mim-conversion"/>
      <Anchor Position="0.43265759511246865" Shape="None" GraphId="aecc9"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="a4d67">
    <Graphics>
      <Point GraphRef="e7910"/>
      <Point GraphRef="da52d" ArrowHead="mim-conversion"/>
      <Anchor Position="0.6842516885886951" Shape="None" GraphId="aaa64"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="a56c3">
    <Graphics ConnectorType="Curved" LineStyle="Broken">
      <Point GraphRef="ab957"/>
      <Point/>
      <Point GraphRef="df27a" ArrowHead="Arrow"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="a6706">
    <Graphics>
      <Point GraphRef="f5b57"/>
      <Point GraphRef="ecb2f" ArrowHead="Arrow"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="a7ec9">
    <Graphics LineStyle="Broken">
      <Point GraphRef="df27a"/>
      <Point GraphRef="aa8b2" ArrowHead="Arrow"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="abb6a">
    <Graphics>
      <Point GraphRef="d9509"/>
      <Point GraphRef="ab957" ArrowHead="mim-conversion"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="af4d8">
    <Graphics>
      <Point GraphRef="fde63"/>
      <Point GraphRef="ae234" ArrowHead="mim-conversion"/>
      <Anchor Position="0.4" Shape="None" GraphId="c4bfe"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="b4726">
    <Graphics ConnectorType="Curved" LineStyle="Broken">
      <Point GraphRef="af674"/>
      <Point/>
      <Point GraphRef="e112d" ArrowHead="Arrow"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="b6257">
    <Graphics>
      <Point GraphRef="ae234"/>
      <Point GraphRef="df25b" ArrowHead="mim-conversion"/>
      <Anchor Position="0.4" Shape="None" GraphId="f627d"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="b7bd5">
    <Graphics>
      <Point GraphRef="e5c13"/>
      <Point GraphRef="f066c" ArrowHead="mim-conversion"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="d6b11">
    <Graphics ConnectorType="Curved">
      <Point GraphRef="df15b"/>
      <Point GraphRef="d93a5" ArrowHead="Arrow"/>
      <Anchor Position="0.3364947097198621" Shape="None" GraphId="abf0a"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="dabeb">
    <Graphics ConnectorType="Curved">
      <Point GraphRef="e7910"/>
      <Point/>
      <Point GraphRef="a6a61" ArrowHead="mim-conversion"/>
      <Anchor Position="0.7936047062774741" Shape="None" GraphId="ca9b9"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="e34e6">
    <Graphics>
      <Point GraphRef="da52d"/>
      <Point GraphRef="d9509" ArrowHead="mim-conversion"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="ec0cc">
    <Graphics ConnectorType="Curved">
      <Point GraphRef="e7910"/>
      <Point/>
      <Point GraphRef="edd9a" ArrowHead="mim-conversion"/>
      <Anchor Position="0.8030852994555353" Shape="None" GraphId="bd02d"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="f3919">
    <Graphics>
      <Point GraphRef="edd9a"/>
      <Point GraphRef="f066c" ArrowHead="mim-conversion"/>
      <Anchor Position="0.46963152433580274" Shape="None" GraphId="bb443"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="f70a6">
    <Graphics>
      <Point GraphRef="e5c13"/>
      <Point GraphRef="af674" ArrowHead="mim-conversion"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="f7f3e">
    <Graphics>
      <Point GraphRef="a6a61"/>
      <Point GraphRef="da52d" ArrowHead="mim-conversion"/>
      <Anchor Position="0.43416370106761565" Shape="None" GraphId="bc754"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id12aaa43">
    <Graphics>
      <Point GraphRef="a4b39"/>
      <Point GraphRef="e7910" ArrowHead="Arrow"/>
      <Anchor Position="0.08956592622783775" Shape="None" GraphId="bfc19"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id1d1d218d">
    <Graphics ConnectorType="Curved" Color="cc0000">
      <Point GraphRef="ef347"/>
      <Point GraphRef="d0969" ArrowHead="mim-inhibition"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id3062cb58">
    <Graphics>
      <Point GraphRef="e59ab"/>
      <Point GraphRef="ec354" ArrowHead="mim-catalysis"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id33e21efd">
    <Graphics>
      <Point GraphRef="f3ee2"/>
      <Point GraphRef="f627d" ArrowHead="mim-catalysis"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id398367f4">
    <Graphics ConnectorType="Curved">
      <Point GraphRef="d93a5"/>
      <Point GraphRef="df15b" ArrowHead="Arrow"/>
      <Anchor Position="0.4" Shape="None" GraphId="a7c0c"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id457a5c0a">
    <Graphics ConnectorType="Curved">
      <Point GraphRef="dfc35"/>
      <Point/>
      <Point GraphRef="e7e11" ArrowHead="mim-conversion"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id459d15de">
    <Graphics>
      <Point GraphRef="f3966"/>
      <Point GraphRef="abf0a" ArrowHead="mim-catalysis"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id4a9f7089">
    <Graphics ConnectorType="Curved">
      <Point GraphRef="c3c32"/>
      <Point GraphRef="b4e64" ArrowHead="mim-conversion"/>
      <Anchor Position="0.4" Shape="None" GraphId="ec354"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id4c9f27d3">
    <Graphics>
      <Point GraphRef="b6c43"/>
      <Point GraphRef="bc754" ArrowHead="mim-catalysis"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id5858aef">
    <Graphics>
      <Point GraphRef="fa212"/>
      <Point GraphRef="eb270" ArrowHead="mim-catalysis"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id687eee0a">
    <Graphics ConnectorType="Curved">
      <Point GraphRef="e7910"/>
      <Point GraphRef="fde63" ArrowHead="mim-conversion"/>
      <Anchor Position="0.6716820517560852" Shape="None" GraphId="d5d2f"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id72ecb3bd">
    <Graphics ConnectorType="Curved">
      <Point GraphRef="d2ec5"/>
      <Point GraphRef="a85a1" ArrowHead="mim-conversion"/>
      <Anchor Position="0.4" Shape="None" GraphId="f6408"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id76e83284">
    <BiopaxRef>c71</BiopaxRef>
    <Graphics>
      <Point GraphRef="c8a9b"/>
      <Point GraphRef="c0e49" ArrowHead="TBar"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id79ab688">
    <Graphics ConnectorType="Curved">
      <Point GraphRef="f1549"/>
      <Point GraphRef="a7f59" ArrowHead="mim-conversion"/>
      <Anchor Position="0.4" Shape="None" GraphId="b4a1c"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id7ab687c3">
    <Graphics>
      <Point GraphRef="c458b"/>
      <Point GraphRef="d0969" ArrowHead="mim-stimulation"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id851cbe0e">
    <Graphics>
      <Point GraphRef="d356e"/>
      <Point GraphRef="c4bfe" ArrowHead="mim-catalysis"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id8e2b4c94">
    <Graphics LineStyle="Broken">
      <Point GraphRef="e112d"/>
      <Point GraphRef="f5b57" ArrowHead="Arrow"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id958f7492">
    <Graphics ConnectorType="Curved">
      <Point GraphRef="a64c7"/>
      <Point GraphRef="f1549" ArrowHead="mim-conversion"/>
      <Anchor Position="0.4" Shape="None" GraphId="e7b6c"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id95afb06">
    <Graphics>
      <Point GraphRef="b82b7"/>
      <Point GraphRef="bfc19" ArrowHead="mim-catalysis"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="ida613aa42">
    <Graphics ConnectorType="Curved">
      <Point GraphRef="b4e64"/>
      <Point GraphRef="e7910" ArrowHead="mim-conversion"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="ida6d98cef">
    <Graphics>
      <Point GraphRef="d1fb1"/>
      <Point GraphRef="bd02d" ArrowHead="mim-catalysis"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="ida833b0dc">
    <Graphics>
      <Point GraphRef="c876f"/>
      <Point GraphRef="d5d2f" ArrowHead="mim-catalysis"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="idad322e8c">
    <Graphics>
      <Point GraphRef="b2eb1"/>
      <Point GraphRef="bb443" ArrowHead="mim-catalysis"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="idb61e6596">
    <Graphics ConnectorType="Curved">
      <Point GraphRef="d8b62"/>
      <Point GraphRef="f5b57" ArrowHead="Arrow"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="idc16416e9">
    <Graphics>
      <Point GraphRef="a7f59"/>
      <Point GraphRef="e7910" ArrowHead="mim-conversion"/>
      <Anchor Position="0.4" Shape="None" GraphId="eb270"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="idc4a8efbd">
    <Graphics ConnectorType="Curved" LineStyle="Broken">
      <Point GraphRef="f066c"/>
      <Point GraphRef="ef347" ArrowHead="Arrow"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="idc5dc2265">
    <Graphics>
      <Point GraphRef="d0969"/>
      <Point GraphRef="f6408" ArrowHead="mim-catalysis"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="idc86511af">
    <Graphics>
      <Point GraphRef="e7910"/>
      <Point GraphRef="a4b39" ArrowHead="Arrow"/>
      <Anchor Position="0.5862776464760097" Shape="None" GraphId="e992a"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="idd70ba36b">
    <Graphics>
      <Point GraphRef="e17b1"/>
      <Point GraphRef="a7c0c" ArrowHead="mim-catalysis"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="iddf753c41">
    <Graphics>
      <Point GraphRef="a5358"/>
      <Point GraphRef="ca9b9" ArrowHead="mim-catalysis"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="ide0cc1150">
    <Graphics>
      <Point GraphRef="ec14a"/>
      <Point GraphRef="aecc9" ArrowHead="mim-catalysis"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="ide44ef481">
    <Graphics>
      <Point GraphRef="c249d"/>
      <Point GraphRef="aaa64" ArrowHead="mim-catalysis"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="ide73fbafd">
    <Graphics>
      <Point GraphRef="c7f6b"/>
      <Point GraphRef="e992a" ArrowHead="mim-catalysis"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="ide98785ae">
    <Graphics>
      <Point GraphRef="bec21"/>
      <Point GraphRef="b4a1c" ArrowHead="mim-catalysis"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="ideb5e8c5b">
    <Graphics>
      <Point GraphRef="aa8b2"/>
      <Point GraphRef="ecb2f" ArrowHead="Arrow"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="idf5559ef0">
    <Graphics>
      <Point GraphRef="fbe3d"/>
      <Point GraphRef="e7b6c" ArrowHead="mim-catalysis"/>
    </Graphics>
    </Interaction>
  <Label TextLabel="RNA Incorporation" GraphId="aa8b2">
    <Graphics FillColor="ffffff" Color="cc3300"/>
  </Label>
  <Label TextLabel="Basolateral membrane" GraphId="ac2e7">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="Reuptake" GraphId="aff35">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="Apical membrane" GraphId="b555f">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="Efflux Drug resistance" GraphId="b624e">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="Liver cell" GraphId="c052d">
    <Graphics FillColor="ffffff" Color="999999"/>
  </Label>
  <Label TextLabel="Cancer cell" GraphId="d0b50">
    <Graphics FillColor="ffffff" Color="999999"/>
  </Label>
  <Label TextLabel="DNA Incorporation" GraphId="f5b57">
    <BiopaxRef>b0a</BiopaxRef>
    <Graphics FillColor="ffffff" Color="cc0000"/>
  </Label>
  <Shape GraphId="f5b88">
    <Graphics ShapeType="RoundedRectangle" Color="cccccc"/>
  </Shape>
  <Shape GraphId="f9a7b">
    <Graphics ShapeType="RoundedRectangle" Color="cccccc"/>
  </Shape>
  <Group GroupId="a284d" GraphId="a5358" Style="Group"/>
  <Group GroupId="a0a40" GraphId="b6c43" Style="Group"/>
  <Group GroupId="d7a41" GraphId="c249d" Style="Group"/>
  <Group GroupId="a95fd" GraphId="c7f6b" Style="Group"/>
  <Group GroupId="f3ea1" GraphId="e17b1" Style="Group">
    <BiopaxRef>d56</BiopaxRef>
  </Group>
  <Group GroupId="f2003" GraphId="ec14a" Style="Group"/>
  <Group GroupId="c474a" GraphId="fa212" Style="Group"/>
  <Group GroupId="d0388" GraphId="fbe3d" Style="Group"/>
  <InfoBox/>
  <Biopax>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f61">
      <bp:ID >16267625</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Thymidylate synthase pharmacogenetics.</bp:TITLE>
      <bp:SOURCE >Invest New Drugs</bp:SOURCE>
      <bp:YEAR >2005</bp:YEAR>
      <bp:AUTHORS >Marsh S</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="dae">
      <bp:ID >18357466</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy.</bp:TITLE>
      <bp:SOURCE >J Cancer Res Clin Oncol</bp:SOURCE>
      <bp:YEAR >2008</bp:YEAR>
      <bp:AUTHORS >Huang ZH</bp:AUTHORS>
      <bp:AUTHORS >Hua D</bp:AUTHORS>
      <bp:AUTHORS >Li LH</bp:AUTHORS>
      <bp:AUTHORS >Zhu JD</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a42">
      <bp:ID >19339911</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity.</bp:TITLE>
      <bp:SOURCE >Pharmacogenet Genomics</bp:SOURCE>
      <bp:YEAR >2009</bp:YEAR>
      <bp:AUTHORS >Peters EJ</bp:AUTHORS>
      <bp:AUTHORS >Kraja AT</bp:AUTHORS>
      <bp:AUTHORS >Lin SJ</bp:AUTHORS>
      <bp:AUTHORS >Yen-Revollo JL</bp:AUTHORS>
      <bp:AUTHORS >Marsh S</bp:AUTHORS>
      <bp:AUTHORS >Province MA</bp:AUTHORS>
      <bp:AUTHORS >McLeod HL</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d56">
      <bp:ID >19077464</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells.</bp:TITLE>
      <bp:SOURCE >Pancreatology</bp:SOURCE>
      <bp:YEAR >2009</bp:YEAR>
      <bp:AUTHORS >Hagmann W</bp:AUTHORS>
      <bp:AUTHORS >Jesnowski R</bp:AUTHORS>
      <bp:AUTHORS >Faissner R</bp:AUTHORS>
      <bp:AUTHORS >Guo C</bp:AUTHORS>
      <bp:AUTHORS >L&#246;hr JM</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e0c">
      <bp:ID >18172246</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?</bp:TITLE>
      <bp:SOURCE >Clin Cancer Res</bp:SOURCE>
      <bp:YEAR >2008</bp:YEAR>
      <bp:AUTHORS >Yen-Revollo JL</bp:AUTHORS>
      <bp:AUTHORS >Goldberg RM</bp:AUTHORS>
      <bp:AUTHORS >McLeod HL</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="b8e">
      <bp:ID >19383847</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance.</bp:TITLE>
      <bp:SOURCE >Mol Cancer Ther</bp:SOURCE>
      <bp:YEAR >2009</bp:YEAR>
      <bp:AUTHORS >Humeniuk R</bp:AUTHORS>
      <bp:AUTHORS >Menon LG</bp:AUTHORS>
      <bp:AUTHORS >Mishra PJ</bp:AUTHORS>
      <bp:AUTHORS >Gorlick R</bp:AUTHORS>
      <bp:AUTHORS >Sowers R</bp:AUTHORS>
      <bp:AUTHORS >Rode W</bp:AUTHORS>
      <bp:AUTHORS >Pizzorno G</bp:AUTHORS>
      <bp:AUTHORS >Cheng YC</bp:AUTHORS>
      <bp:AUTHORS >Kemeny N</bp:AUTHORS>
      <bp:AUTHORS >Bertino JR</bp:AUTHORS>
      <bp:AUTHORS >Banerjee D</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="dfc">
      <bp:ID >1272473</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Incorporation of 3H-dibromodulcitol and 3H-dianhydrodulcitol into ascites tumor cells. Autoradiographic study.</bp:TITLE>
      <bp:SOURCE >Neoplasma</bp:SOURCE>
      <bp:YEAR >1976</bp:YEAR>
      <bp:ID >12724731</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >5-fluorouracil: mechanisms of action and clinical strategies.</bp:TITLE>
      <bp:SOURCE >Nat Rev Cancer</bp:SOURCE>
      <bp:YEAR >2003</bp:YEAR>
      <bp:AUTHORS >Longley DB</bp:AUTHORS>
      <bp:AUTHORS >Harkin DP</bp:AUTHORS>
      <bp:AUTHORS >Johnston PG</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#">
      <bp:TERM xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >drug pathway</bp:TERM>
      <bp:ID xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >PW:0000754</bp:ID>
      <bp:Ontology xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >Pathway Ontology</bp:Ontology>
    </bp:openControlledVocabulary>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="bf9">
      <bp:ID >15548681</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Mechanistic and predictive profiling of 5-Fluorouracil resistance in human cancer cells.</bp:TITLE>
      <bp:SOURCE >Cancer Res</bp:SOURCE>
      <bp:YEAR >2004</bp:YEAR>
      <bp:AUTHORS >Wang W</bp:AUTHORS>
      <bp:AUTHORS >Cassidy J</bp:AUTHORS>
      <bp:AUTHORS >O'Brien V</bp:AUTHORS>
      <bp:AUTHORS >Ryan KM</bp:AUTHORS>
      <bp:AUTHORS >Collie-Duguid E</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="c1f">
      <bp:ID >9849491</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.</bp:TITLE>
      <bp:SOURCE >Eur J Cancer</bp:SOURCE>
      <bp:YEAR >1998</bp:YEAR>
      <bp:AUTHORS >Miwa M</bp:AUTHORS>
      <bp:AUTHORS >Ura M</bp:AUTHORS>
      <bp:AUTHORS >Nishida M</bp:AUTHORS>
      <bp:AUTHORS >Sawada N</bp:AUTHORS>
      <bp:AUTHORS >Ishikawa T</bp:AUTHORS>
      <bp:AUTHORS >Mori K</bp:AUTHORS>
      <bp:AUTHORS >Shimma N</bp:AUTHORS>
      <bp:AUTHORS >Umeda I</bp:AUTHORS>
      <bp:AUTHORS >Ishitsuka H</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a64">
      <bp:ID >18498133</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival.</bp:TITLE>
      <bp:SOURCE >Int J Cancer</bp:SOURCE>
      <bp:YEAR >2008</bp:YEAR>
      <bp:AUTHORS >Nordgard SH</bp:AUTHORS>
      <bp:AUTHORS >Alnaes GI</bp:AUTHORS>
      <bp:AUTHORS >Hihn B</bp:AUTHORS>
      <bp:AUTHORS >Lingjaerde OC</bp:AUTHORS>
      <bp:AUTHORS >Liest&#195;&#402;&#194;&#184;l K</bp:AUTHORS>
      <bp:AUTHORS >Tsalenko A</bp:AUTHORS>
      <bp:AUTHORS >S&#195;&#402;&#194;&#184;rlie T</bp:AUTHORS>
      <bp:AUTHORS >L&#195;&#402;&#194;&#184;nning PE</bp:AUTHORS>
      <bp:AUTHORS >B&#195;&#402;&#194;&#184;rresen-Dale AL</bp:AUTHORS>
      <bp:AUTHORS >Kristensen VN</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a3c">
      <bp:ID >2656050</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Clinical pharmacology of 5-fluorouracil.</bp:TITLE>
      <bp:SOURCE >Clin Pharmacokinet</bp:SOURCE>
      <bp:YEAR >1989</bp:YEAR>
      <bp:AUTHORS >Diasio RB</bp:AUTHORS>
      <bp:AUTHORS >Harris BE</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#">
      <bp:TERM xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >cancer</bp:TERM>
      <bp:ID xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >DOID:162</bp:ID>
      <bp:Ontology xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >Disease</bp:Ontology>
    </bp:openControlledVocabulary>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="b9d">
      <bp:ID >16709241</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery.</bp:TITLE>
      <bp:SOURCE >Mol Cancer</bp:SOURCE>
      <bp:YEAR >2006</bp:YEAR>
      <bp:AUTHORS >De Angelis PM</bp:AUTHORS>
      <bp:AUTHORS >Svendsrud DH</bp:AUTHORS>
      <bp:AUTHORS >Kravik KL</bp:AUTHORS>
      <bp:AUTHORS >Stokke T</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ff5">
      <bp:ID >15638735</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Novel chemical strategies for thymidylate synthase inhibition.</bp:TITLE>
      <bp:SOURCE >Curr Med Chem</bp:SOURCE>
      <bp:YEAR >2005</bp:YEAR>
      <bp:AUTHORS >Gmeiner WH</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a45">
      <bp:ID >19219653</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Expression profiling of nucleotide metabolism-related genes in human breast cancer cells after treatment with 5-fluorouracil.</bp:TITLE>
      <bp:SOURCE >Cancer Invest</bp:SOURCE>
      <bp:YEAR >2009</bp:YEAR>
      <bp:AUTHORS >Behera RK</bp:AUTHORS>
      <bp:AUTHORS >Nayak R</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f4c">
      <bp:ID >18820913</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer.</bp:TITLE>
      <bp:SOURCE >Cancer Chemother Pharmacol</bp:SOURCE>
      <bp:YEAR >2009</bp:YEAR>
      <bp:AUTHORS >Yuan J</bp:AUTHORS>
      <bp:AUTHORS >Lv H</bp:AUTHORS>
      <bp:AUTHORS >Peng B</bp:AUTHORS>
      <bp:AUTHORS >Wang C</bp:AUTHORS>
      <bp:AUTHORS >Yu Y</bp:AUTHORS>
      <bp:AUTHORS >He Z</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="aa3">
      <bp:ID >18267032</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >ERCC2 2251A&gt;C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study.</bp:TITLE>
      <bp:SOURCE >BMC Cancer</bp:SOURCE>
      <bp:YEAR >2008</bp:YEAR>
      <bp:AUTHORS >Huang MY</bp:AUTHORS>
      <bp:AUTHORS >Fang WY</bp:AUTHORS>
      <bp:AUTHORS >Lee SC</bp:AUTHORS>
      <bp:AUTHORS >Cheng TL</bp:AUTHORS>
      <bp:AUTHORS >Wang JY</bp:AUTHORS>
      <bp:AUTHORS >Lin SR</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ffd">
      <bp:ID >11956089</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines.</bp:TITLE>
      <bp:SOURCE >Cancer Res</bp:SOURCE>
      <bp:YEAR >2002</bp:YEAR>
      <bp:AUTHORS >Cao D</bp:AUTHORS>
      <bp:AUTHORS >Russell RL</bp:AUTHORS>
      <bp:AUTHORS >Zhang D</bp:AUTHORS>
      <bp:AUTHORS >Leffert JJ</bp:AUTHORS>
      <bp:AUTHORS >Pizzorno G</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f96">
      <bp:ID >17549067</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.</bp:TITLE>
      <bp:SOURCE >Pharmacogenomics J</bp:SOURCE>
      <bp:YEAR >2008</bp:YEAR>
      <bp:AUTHORS >Ruzzo A</bp:AUTHORS>
      <bp:AUTHORS >Graziano F</bp:AUTHORS>
      <bp:AUTHORS >Loupakis F</bp:AUTHORS>
      <bp:AUTHORS >Santini D</bp:AUTHORS>
      <bp:AUTHORS >Catalano V</bp:AUTHORS>
      <bp:AUTHORS >Bisonni R</bp:AUTHORS>
      <bp:AUTHORS >Ficarelli R</bp:AUTHORS>
      <bp:AUTHORS >Fontana A</bp:AUTHORS>
      <bp:AUTHORS >Andreoni F</bp:AUTHORS>
      <bp:AUTHORS >Falcone A</bp:AUTHORS>
      <bp:AUTHORS >Canestrari E</bp:AUTHORS>
      <bp:AUTHORS >Tonini G</bp:AUTHORS>
      <bp:AUTHORS >Mari D</bp:AUTHORS>
      <bp:AUTHORS >Lippe P</bp:AUTHORS>
      <bp:AUTHORS >Pizzagalli F</bp:AUTHORS>
      <bp:AUTHORS >Schiavon G</bp:AUTHORS>
      <bp:AUTHORS >Alessandroni P</bp:AUTHORS>
      <bp:AUTHORS >Giustini L</bp:AUTHORS>
      <bp:AUTHORS >Maltese P</bp:AUTHORS>
      <bp:AUTHORS >Testa E</bp:AUTHORS>
      <bp:AUTHORS >Menichetti ET</bp:AUTHORS>
      <bp:AUTHORS >Magnani M</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ad5">
      <bp:ID >19093176</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup?</bp:TITLE>
      <bp:SOURCE >Int J Clin Oncol</bp:SOURCE>
      <bp:YEAR >2008</bp:YEAR>
      <bp:AUTHORS >Iacopetta B</bp:AUTHORS>
      <bp:AUTHORS >Kawakami K</bp:AUTHORS>
      <bp:AUTHORS >Watanabe T</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="b66">
      <bp:ID >19302291</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells.</bp:TITLE>
      <bp:SOURCE >Cancer Sci</bp:SOURCE>
      <bp:YEAR >2009</bp:YEAR>
      <bp:AUTHORS >Karasawa H</bp:AUTHORS>
      <bp:AUTHORS >Miura K</bp:AUTHORS>
      <bp:AUTHORS >Fujibuchi W</bp:AUTHORS>
      <bp:AUTHORS >Ishida K</bp:AUTHORS>
      <bp:AUTHORS >Kaneko N</bp:AUTHORS>
      <bp:AUTHORS >Kinouchi M</bp:AUTHORS>
      <bp:AUTHORS >Okabe M</bp:AUTHORS>
      <bp:AUTHORS >Ando T</bp:AUTHORS>
      <bp:AUTHORS >Murata Y</bp:AUTHORS>
      <bp:AUTHORS >Sasaki H</bp:AUTHORS>
      <bp:AUTHORS >Takami K</bp:AUTHORS>
      <bp:AUTHORS >Yamamura A</bp:AUTHORS>
      <bp:AUTHORS >Shibata C</bp:AUTHORS>
      <bp:AUTHORS >Sasaki I</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f20">
      <bp:ID >16510598</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer.</bp:TITLE>
      <bp:SOURCE >Cancer Res</bp:SOURCE>
      <bp:YEAR >2006</bp:YEAR>
      <bp:AUTHORS >Boyer J</bp:AUTHORS>
      <bp:AUTHORS >Allen WL</bp:AUTHORS>
      <bp:AUTHORS >McLean EG</bp:AUTHORS>
      <bp:AUTHORS >Wilson PM</bp:AUTHORS>
      <bp:AUTHORS >McCulla A</bp:AUTHORS>
      <bp:AUTHORS >Moore S</bp:AUTHORS>
      <bp:AUTHORS >Longley DB</bp:AUTHORS>
      <bp:AUTHORS >Caldas C</bp:AUTHORS>
      <bp:AUTHORS >Johnston PG</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#">
      <bp:TERM xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >hepatocyte</bp:TERM>
      <bp:ID xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >CL:0000182</bp:ID>
      <bp:Ontology xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >Cell Type</bp:Ontology>
    </bp:openControlledVocabulary>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="dd6">
      <bp:ID >8996164</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation.</bp:TITLE>
      <bp:SOURCE >J Clin Oncol</bp:SOURCE>
      <bp:YEAR >1997</bp:YEAR>
      <bp:AUTHORS >Sobrero AF</bp:AUTHORS>
      <bp:AUTHORS >Aschele C</bp:AUTHORS>
      <bp:AUTHORS >Bertino JR</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="cae">
      <bp:ID >17283124</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity.</bp:TITLE>
      <bp:SOURCE >Cancer Res</bp:SOURCE>
      <bp:YEAR >2007</bp:YEAR>
      <bp:AUTHORS >An Q</bp:AUTHORS>
      <bp:AUTHORS >Robins P</bp:AUTHORS>
      <bp:AUTHORS >Lindahl T</bp:AUTHORS>
      <bp:AUTHORS >Barnes DE</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="cf4">
      <bp:ID >18992248</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.</bp:TITLE>
      <bp:SOURCE >Gastroenterology</bp:SOURCE>
      <bp:YEAR >2009</bp:YEAR>
      <bp:AUTHORS >Farrell JJ</bp:AUTHORS>
      <bp:AUTHORS >Elsaleh H</bp:AUTHORS>
      <bp:AUTHORS >Garcia M</bp:AUTHORS>
      <bp:AUTHORS >Lai R</bp:AUTHORS>
      <bp:AUTHORS >Ammar A</bp:AUTHORS>
      <bp:AUTHORS >Regine WF</bp:AUTHORS>
      <bp:AUTHORS >Abrams R</bp:AUTHORS>
      <bp:AUTHORS >Benson AB</bp:AUTHORS>
      <bp:AUTHORS >Macdonald J</bp:AUTHORS>
      <bp:AUTHORS >Cass CE</bp:AUTHORS>
      <bp:AUTHORS >Dicker AP</bp:AUTHORS>
      <bp:AUTHORS >Mackey JR</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="c71">
      <bp:ID >18390668</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins.</bp:TITLE>
      <bp:SOURCE >Proc Natl Acad Sci U S A</bp:SOURCE>
      <bp:YEAR >2008</bp:YEAR>
      <bp:AUTHORS >Sengupta S</bp:AUTHORS>
      <bp:AUTHORS >den Boon JA</bp:AUTHORS>
      <bp:AUTHORS >Chen IH</bp:AUTHORS>
      <bp:AUTHORS >Newton MA</bp:AUTHORS>
      <bp:AUTHORS >Stanhope SA</bp:AUTHORS>
      <bp:AUTHORS >Cheng YJ</bp:AUTHORS>
      <bp:AUTHORS >Chen CJ</bp:AUTHORS>
      <bp:AUTHORS >Hildesheim A</bp:AUTHORS>
      <bp:AUTHORS >Sugden B</bp:AUTHORS>
      <bp:AUTHORS >Ahlquist P</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ba0">
      <bp:ID >14555507</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity.</bp:TITLE>
      <bp:SOURCE >Clin Cancer Res</bp:SOURCE>
      <bp:YEAR >2003</bp:YEAR>
      <bp:AUTHORS >van Kuilenburg AB</bp:AUTHORS>
      <bp:AUTHORS >Meinsma R</bp:AUTHORS>
      <bp:AUTHORS >Zonnenberg BA</bp:AUTHORS>
      <bp:AUTHORS >Zoetekouw L</bp:AUTHORS>
      <bp:AUTHORS >Baas F</bp:AUTHORS>
      <bp:AUTHORS >Matsuda K</bp:AUTHORS>
      <bp:AUTHORS >Tamaki N</bp:AUTHORS>
      <bp:AUTHORS >van Gennip AH</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d5d">
      <bp:ID >18837291</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Breast cancer resistance protein expression and 5-fluorouracil resistance.</bp:TITLE>
      <bp:SOURCE >Biomed Environ Sci</bp:SOURCE>
      <bp:YEAR >2008</bp:YEAR>
      <bp:AUTHORS >Yuan JH</bp:AUTHORS>
      <bp:AUTHORS >Cheng JQ</bp:AUTHORS>
      <bp:AUTHORS >Jiang LY</bp:AUTHORS>
      <bp:AUTHORS >Ji WD</bp:AUTHORS>
      <bp:AUTHORS >Guo LF</bp:AUTHORS>
      <bp:AUTHORS >Liu JJ</bp:AUTHORS>
      <bp:AUTHORS >Xu XY</bp:AUTHORS>
      <bp:AUTHORS >He JS</bp:AUTHORS>
      <bp:AUTHORS >Wang XM</bp:AUTHORS>
      <bp:AUTHORS >Zhuang ZX</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="cb2">
      <bp:ID >18075467</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism.</bp:TITLE>
      <bp:SOURCE >Pharmacogenet Genomics</bp:SOURCE>
      <bp:YEAR >2007</bp:YEAR>
      <bp:AUTHORS >Thomas HR</bp:AUTHORS>
      <bp:AUTHORS >Ezzeldin HH</bp:AUTHORS>
      <bp:AUTHORS >Guarcello V</bp:AUTHORS>
      <bp:AUTHORS >Mattison LK</bp:AUTHORS>
      <bp:AUTHORS >Fridley BL</bp:AUTHORS>
      <bp:AUTHORS >Diasio RB</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e25">
      <bp:ID >18607850</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.</bp:TITLE>
      <bp:SOURCE >Acta Oncol</bp:SOURCE>
      <bp:YEAR >2008</bp:YEAR>
      <bp:AUTHORS >Jensen SA</bp:AUTHORS>
      <bp:AUTHORS >Vainer B</bp:AUTHORS>
      <bp:AUTHORS >Witton CJ</bp:AUTHORS>
      <bp:AUTHORS >J&#195;&#402;&#194;&#184;rgensen JT</bp:AUTHORS>
      <bp:AUTHORS >S&#195;&#402;&#194;&#184;rensen JB</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d42">
      <bp:ID >19144510</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation.</bp:TITLE>
      <bp:SOURCE >Eur J Cancer</bp:SOURCE>
      <bp:YEAR >2009</bp:YEAR>
      <bp:AUTHORS >De Mattia E</bp:AUTHORS>
      <bp:AUTHORS >Toffoli G</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="b0a">
      <bp:ID >19402749</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil.</bp:TITLE>
      <bp:SOURCE >PLoS Biol</bp:SOURCE>
      <bp:YEAR >2009</bp:YEAR>
      <bp:AUTHORS >Kunz C</bp:AUTHORS>
      <bp:AUTHORS >Focke F</bp:AUTHORS>
      <bp:AUTHORS >Saito Y</bp:AUTHORS>
      <bp:AUTHORS >Schuermann D</bp:AUTHORS>
      <bp:AUTHORS >Lettieri T</bp:AUTHORS>
      <bp:AUTHORS >Selfridge J</bp:AUTHORS>
      <bp:AUTHORS >Sch&#195;&#402;&#194;&#164;r P</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d3c">
      <bp:ID >15814641</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer.</bp:TITLE>
      <bp:SOURCE >Clin Cancer Res</bp:SOURCE>
      <bp:YEAR >2005</bp:YEAR>
      <bp:AUTHORS >Kidd EA</bp:AUTHORS>
      <bp:AUTHORS >Yu J</bp:AUTHORS>
      <bp:AUTHORS >Li X</bp:AUTHORS>
      <bp:AUTHORS >Shannon WD</bp:AUTHORS>
      <bp:AUTHORS >Watson MA</bp:AUTHORS>
      <bp:AUTHORS >McLeod HL</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="bb0">
      <bp:ID >15901346</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]).</bp:TITLE>
      <bp:SOURCE >J Pharm Pharmacol</bp:SOURCE>
      <bp:YEAR >2005</bp:YEAR>
      <bp:AUTHORS >Kobayashi Y</bp:AUTHORS>
      <bp:AUTHORS >Ohshiro N</bp:AUTHORS>
      <bp:AUTHORS >Sakai R</bp:AUTHORS>
      <bp:AUTHORS >Ohbayashi M</bp:AUTHORS>
      <bp:AUTHORS >Kohyama N</bp:AUTHORS>
      <bp:AUTHORS >Yamamoto T</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="fa0">
      <bp:ID >16785472</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.</bp:TITLE>
      <bp:SOURCE >J Clin Oncol</bp:SOURCE>
      <bp:YEAR >2006</bp:YEAR>
      <bp:AUTHORS >Wu X</bp:AUTHORS>
      <bp:AUTHORS >Gu J</bp:AUTHORS>
      <bp:AUTHORS >Wu TT</bp:AUTHORS>
      <bp:AUTHORS >Swisher SG</bp:AUTHORS>
      <bp:AUTHORS >Liao Z</bp:AUTHORS>
      <bp:AUTHORS >Correa AM</bp:AUTHORS>
      <bp:AUTHORS >Liu J</bp:AUTHORS>
      <bp:AUTHORS >Etzel CJ</bp:AUTHORS>
      <bp:AUTHORS >Amos CI</bp:AUTHORS>
      <bp:AUTHORS >Huang M</bp:AUTHORS>
      <bp:AUTHORS >Chiang SS</bp:AUTHORS>
      <bp:AUTHORS >Milas L</bp:AUTHORS>
      <bp:AUTHORS >Hittelman WN</bp:AUTHORS>
      <bp:AUTHORS >Ajani JA</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e79">
      <bp:ID >18035049</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Folylpolyglutamate synthase and gamma-glutamyl hydrolase regulate leucovorin-enhanced 5-fluorouracil anticancer activity.</bp:TITLE>
      <bp:SOURCE >Biochem Biophys Res Commun</bp:SOURCE>
      <bp:YEAR >2008</bp:YEAR>
      <bp:AUTHORS >Sakamoto E</bp:AUTHORS>
      <bp:AUTHORS >Tsukioka S</bp:AUTHORS>
      <bp:AUTHORS >Oie S</bp:AUTHORS>
      <bp:AUTHORS >Kobunai T</bp:AUTHORS>
      <bp:AUTHORS >Tsujimoto H</bp:AUTHORS>
      <bp:AUTHORS >Sakamoto K</bp:AUTHORS>
      <bp:AUTHORS >Okayama Y</bp:AUTHORS>
      <bp:AUTHORS >Sugimoto Y</bp:AUTHORS>
      <bp:AUTHORS >Oka T</bp:AUTHORS>
      <bp:AUTHORS >Fukushima M</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="c39">
      <bp:ID >17716232</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >G&gt;C SNP of thymidylate synthase with respect to colorectal cancer.</bp:TITLE>
      <bp:SOURCE >Pharmacogenomics</bp:SOURCE>
      <bp:YEAR >2007</bp:YEAR>
      <bp:AUTHORS >Gusella M</bp:AUTHORS>
      <bp:AUTHORS >Padrini R</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e3f">
      <bp:ID >17695509</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.</bp:TITLE>
      <bp:SOURCE >Anticancer Res</bp:SOURCE>
      <bp:YEAR >2007</bp:YEAR>
      <bp:AUTHORS >Tsujie M</bp:AUTHORS>
      <bp:AUTHORS >Nakamori S</bp:AUTHORS>
      <bp:AUTHORS >Nakahira S</bp:AUTHORS>
      <bp:AUTHORS >Takahashi Y</bp:AUTHORS>
      <bp:AUTHORS >Hayashi N</bp:AUTHORS>
      <bp:AUTHORS >Okami J</bp:AUTHORS>
      <bp:AUTHORS >Nagano H</bp:AUTHORS>
      <bp:AUTHORS >Dono K</bp:AUTHORS>
      <bp:AUTHORS >Umeshita K</bp:AUTHORS>
      <bp:AUTHORS >Sakon M</bp:AUTHORS>
      <bp:AUTHORS >Monden M</bp:AUTHORS>
    </bp:PublicationXref>
  <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"><bp:TERM>cancer pathway</bp:TERM><bp:ID>PW:0000605</bp:ID><bp:Ontology>Pathway Ontology</bp:Ontology></bp:openControlledVocabulary></Biopax>
</Pathway>